Astellas reports positive data from real-world Qutenza trials
3 September 2012 11:14 in Pharmaceutical Company Product News
Astellas' patch-based therapy for peripheral neuropathic pain Qutenza has demonstrated a positive performance in a pair of real-world studies.
The eight percent capsaicin patch was shown in a Scandinavian observational study to deliver efficacy and tolerability in 211 non-diabetic patients with different peripheral neuropathic pain conditions.
Meanwhile, a separate trial held in the Czech Republic revealed that the product was able to provide quality of life improvements, while addressing concomitant medication concerns.
The most commonly reported side effects were transient and self-limiting application site reactions, such as mild to moderate pain and erythaema.
Dr Tomas Dolezal at the Institute of Health Economics and Technology Assessment in Prague said: "Our study showed there are high unmet needs in this patient population and the eight percent capsaicin patch offers an effective treatment for peripheral neuropathic pain, providing long-term pain relief and improved quality of life."
Last month, Astellas and partner Medivation published positive clinical trial data underlining the clinical benefits of the new prostate cancer therapy enzalutamide.
Other news stories from 03/09/2012
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency